Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin (AUC2) weekly in combination with paclitaxel 80 mg/m^2 followed by dose dense doxorubicin cyclophosphamide therapy for reimbursement as a treatment option for the neoadjuvant treatment of triple negative breast carcinoma.
This is written in the approval document as:
Neoadjuvant treatment of triple negative breast carcinoma
Citation
CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy - Triple Negative Breast Cancer Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/734-carboplatin-auc-2-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-cyclophosphamide-therapy-triple-negative-breast-cancer-therapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel |